Cargando…

Correlation between changes of pelvic bone marrow fat content and hematological toxicity in concurrent chemoradiotherapy for cervical cancer

OBJECTIVES: To quantify the pelvic bone marrow (PBM) fat content changes receiving different radiation doses of concurrent chemoradiotherapy for cervical cancer and to determine association with peripheral blood cell counts. METHODS: The data of 54 patients were prospectively collected. Patients und...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Cong, Qin, Xiaohang, Gong, Guanzhong, Wang, Lizhen, Su, Ya, Yin, Yong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8991809/ https://www.ncbi.nlm.nih.gov/pubmed/35392934 http://dx.doi.org/10.1186/s13014-022-02029-y

Ejemplares similares

Functional MRI radiomics-based assessment of pelvic bone marrow changes after concurrent chemoradiotherapy for cervical cancer
por: Qin, Xiaohang, et al.
Publicado: (2022)

The relationship between the radiation dose of pelvic-bone marrow and lymphocytic toxicity in concurrent chemoradiotherapy for cervical cancer
por: Zhang, Bao-Zhong, et al.
Publicado: (2023)

Dosimetric evaluation of bone marrow sparing in proton radiotherapy for cervical cancer guided by MR functional imaging
por: Qin, Xiaohang, et al.
Publicado: (2022)

Correlation between pelvic bone marrow radiation dose and acute hematological toxicity in cervical cancer patients treated with concurrent chemoradiation
por: Kumar, T, et al.
Publicado: (2019)

Pelvic bone marrow sparing intensity modulated radiotherapy reduces the incidence of the hematologic toxicity of patients with cervical cancer receiving concurrent chemoradiotherapy: a single-center prospective randomized controlled trial
por: Huang, Jin, et al.
Publicado: (2020)

Comparison of hematological toxicities between innovator and generic cisplatin formulations in cervical cancer patients treated with concurrent chemoradiotherapy
por: Oike, Takahiro, et al.
Publicado: (2013)

The impact of bone marrow irradiation dose on acute haematologic toxicity in cervical cancer patients treated with concurrent chemoradiotherapy
por: Chen, Min, et al.
Publicado: (2023)

Association Between Bone Marrow Dosimetric Parameters and Acute Hematologic Toxicity in Cervical Cancer Patients Undergoing Concurrent Chemoradiotherapy: Comparison of Three-Dimensional Conformal Radiotherapy and Intensity-Modulated Radiation Therapy
por: Hui, Beina, et al.
Publicado: (2014)

Outcome and toxicity of radical radiotherapy or concurrent Chemoradiotherapy for elderly cervical cancer women
por: Wang, Weiping, et al.
Publicado: (2017)

The effect of radiotherapy time and dose on acute hematologic toxicity during concurrent postoperative chemoradiotherapy for early high-risk cervical cancer
por: Yang, Xiaojing, et al.
Publicado: (2023)

Comparison of Hematologic Toxicity and Bone Marrow Compensatory Response in Head and Neck vs. Cervical Cancer Patients Undergoing Chemoradiotherapy
por: Vitzthum, Lucas K., et al.
Publicado: (2020)

Impact of hematologic toxicities during concurrent chemoradiation for cervical cancer
por: Shi, Feiya, et al.
Publicado: (2022)

Individualized pelvic lymphadenectomy should follow neoadjuvant concurrent chemoradiotherapy for locally advanced cervical cancer
por: Wei, Li-Chun, et al.
Publicado: (2018)

Hematological Toxicities of Concurrent Chemoradiotherapies in Head and Neck Cancers: Comparison Among Cisplatin, Nedaplatin, Lobaplatin, and Nimotuzumab
por: Wu, Qiuji, et al.
Publicado: (2021)

Development of a nomogram for predicting grade 2 or higher acute hematologic toxicity of cervical cancer after the pelvic bone marrow sparing radiotherapy
por: Meng, Xiangdi, et al.
Publicado: (2022)

Dose–volume parameters of MRI-based active bone marrow predict hematologic toxicity of chemoradiotherapy for rectal cancer
por: Kuncman, Łukasz, et al.
Publicado: (2020)

Hematologic Markers as Prognostic Factors in Nonmetastatic Esophageal Cancer Patients under Concurrent Chemoradiotherapy
por: Wu, Yi-Feng, et al.
Publicado: (2019)

Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in nasopharyngeal carcinoma patients with cervical nodal necrosis
por: Lan, Mei, et al.
Publicado: (2017)

A prospective single-arm study on the relationship between dose-volume parameters of pelvic functional bone marrow and acute hematological toxicities during intensity-modulated radiotherapy with or without concurrent chemotherapy for uterine cervical/endometrial cancer
por: Chen, Hongbo, et al.
Publicado: (2023)

Extrafascial hysterectomy after concurrent chemoradiotherapy in locally advanced cervical adenocarcinoma
por: Yang, Jie, et al.
Publicado: (2016)

Predictors of Acute Hematologic Toxicity in Women Receiving Extended-Field Chemoradiation for Cervical Cancer: Do Known Pelvic Radiation Bone Marrow Constraints Apply?
por: Hara, Jared H.L., et al.
Publicado: (2022)

Concurrent Chemoradiotherapy without Brachytherapy in Locally Advanced Cervical Cancer
por: Kadkhodayan, Sima, et al.
Publicado: (2013)

Quality of Life in Cervical Cancer Survivors Treated with Concurrent Chemoradiotherapy
por: Stuopelytė, Raminta, et al.
Publicado: (2023)

Radiographic Number of Positive Pelvic Lymph Nodes as a Prognostic Factor in Cervical Cancer Treated With Definitive Concurrent Chemoradiotherapy or Intensity-Modulated Radiotherapy
por: Wang, Shih-Chang, et al.
Publicado: (2018)

Efficacy and toxicity of different concurrent chemoradiotherapy regimens in the treatment of advanced cervical cancer: A network meta-analysis
por: Fu, Zhan-Zhao, et al.
Publicado: (2017)

Sarcopenia Is Associated With Hematologic Toxicity During Chemoradiotherapy in Patients With Anal Carcinoma
por: Martin, Daniel, et al.
Publicado: (2020)

Acute chemoradiotherapy toxicity in cervical cancer patients
por: Radojevic, Marija Zivkovic, et al.
Publicado: (2020)

Concurrent chemoradiotherapy followed by adjuvant chemotherapy versus concurrent chemoradiotherapy alone in locally advanced cervical cancer: A systematic review and meta-analysis
por: Liu, Haonan, et al.
Publicado: (2022)

Significance of Concurrent Chemoradiotherapy as Primary Treatment in Patients with Metastatic Cervical Cancer
por: Hattori, Satomi, et al.
Publicado: (2021)

The efficacy and safety of induction chemotherapy combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in nasopharyngeal carcinoma patients: a systematic review and meta-analysis
por: Wang, Bi-Cheng, et al.
Publicado: (2020)

Role of (18)FDG PET/CT metabolic parameters in predicting hematological toxicity during chemoradiotherapy for locally advanced cervical cancer
por: Meng, Tianyu, et al.
Publicado: (2022)

Comparison of Induction Chemotherapy Plus Concurrent Chemoradiotherapy and Concurrent Chemoradiotherapy Alone in Locally Advanced Nasopharyngeal Carcinoma
por: Xu, Guoqiang, et al.
Publicado: (2021)

Lumican is a potential predictor on the efficacy of concurrent chemoradiotherapy in cervical squamous cell carcinoma
por: Hu, Ge, et al.
Publicado: (2023)

Concurrent Hematologic and Metastatic Epithelial Malignancies in the Bone Marrow: Report of Three Cases
por: Chang, Jeonghyun, et al.
Publicado: (2015)

Adjuvant hysterectomy in patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy
por: Shim, Seung-Hyuk
Publicado: (2019)

Secondary uterine carcinosarcoma after concurrent chemoradiotherapy for cervical cancer: Case reports
por: Wakayama, Akihiko, et al.
Publicado: (2017)

The volume of (99m)Tc sulfur colloid SPET‐defined active bone marrow can predict grade 3 or higher acute hematologic toxicity in locally advanced cervical cancer patients who receive chemoradiotherapy
por: Wang, Shan‐Bing, et al.
Publicado: (2019)

Dosimetric predictors and Lyman normal tissue complication probability model of hematological toxicity in cervical cancer patients with treated with pelvic irradiation
por: Wang, Dandan, et al.
Publicado: (2021)

Response of FDG avid pelvic bone marrow to concurrent chemoradiation for anal cancer
por: Robinson, Maxwell, et al.
Publicado: (2020)

Concurrent chemoradiotherapy with S-1 compared with concurrent chemoradiotherapy with docetaxel and cisplatin for locally advanced esophageal squamous cell carcinoma
por: Zhou, Xi-Lei, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_aumk3ok3fhff0rtth35d5hkmcb